HSIC

Henry Schein, Inc. (HSIC) | Rumor.io

Henry Schein

HSIC

Attention (50-day avg)0%

Attention rank (50-day avg)#3,702

Bullish sentiment (50-day avg)100%

Price to earnings ratio25.1

Market capitalization9.8B

Earnings per share3.43

Dividend yield (TTM)—

Revenue (annual)13.2B

Net income (annual)419M

Social

What share of all stock conversation is about HSIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 4

$HSIC reported Q2 FY26 results with strong sales and earnings growth, beating estimates on both revenue and EPS.
Management raised full-year guidance across the board, including a subtle but meaningful upgrade to EBITDA growth expectations.
Henry Schein's Q2 FY26 GAAP diluted EPS was $0.82, and total net sales were $3.5 billion, an increase of 6.7% compared to the same period last year.

Generated by AI

Sentiment

Of the messages about HSIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.74% -13.94
Bearish	—	—	—	40.26% +13.94

Bullish· Feb 24

$HSIC's Q4 2025 earnings beat expectations, with a 7.7% YoY revenue growth and a 4.0% full-year revenue growth.
The company's positive 2026 outlook and $850M share buyback plan indicate a strong financial position and potential for future growth.
$HSIC's stock price surged 4.8% post-earnings, with a revenue beat and underlying strength in the bottom-line growth suggesting a potential momentum shift.

Bearish· Dec 6

Henry Schein has been downgraded to underweight by Morgan Stanley, indicating a bearish outlook on the company's stock.
The stock's price may continue to drop, potentially reaching as low as $60 or $52, due to a broader market correction and similar historical patterns.
Shorting Henry Schein and another company, PDCO, may be a viable strategy following news that they have become targets of a larger company, dubbed the "Death Star".

Generated by AI

Topics

Of the messages about HSIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	59.6%
Analysts	—	—	0%	10.4%
Earnings	—	—	0%	13.2%
Controversies	—	—	0%	0%
Macro	—	—	0%	4%
Technical Analysis	—	—	0%	12.8%

Earnings· Nov 13

Henry Schein's Q3 earnings met expectations at $1.32 per share, but revenue missed the consensus at $3.16 billion, a 3.1% year-over-year increase.
The company lowered its full-year 2023 guidance for adjusted EPS to $4.43-$4.71, citing softening macroeconomic conditions and a business interruption impact from a cybersecurity incident.
Henry Schein's Q3 revenue growth was driven by stable net sales, with total net sales reaching $3.2 billion, an increase of 3.1% compared to the third quarter of 2022.

Analysts· Feb 16

Morgan Stanley analyst Erin Wright maintains Henry Schein ($HSIC) with an Underweight rating and raises the price target from $67 to $72.
Credit Suisse analyst Matt Miksic maintains Henry Schein ($HSIC) with an Outperform rating and raises the price target from $90 to $100.
Robert W. Baird and Barrington Research have raised their price targets for Henry Schein ($HSIC) to $103.00 and $102.00, respectively.

Announcements· Nov 13

Henry Schein, Inc. ($HSIC) reported Q3 2023 financial results, with adjusted EPS of $1.32 and revenue of $3.2B, missing consensus estimates.
The company updated its full-year guidance, lowering adjusted EPS to $4.43-$4.71 and revenue outlook to -3% to -1% due to a softening macro picture and a cybersecurity incident.
Henry Schein's shares fell 3.07% in pre-market trading after the report, citing lower sales of PPE products and COVID-19 test kits, but the company's technology, value-added services, and dental specialty products contributed to profitability.

Generated by AI

Community

Of the messages about HSIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	31.63%
Newcomers	—	—	100%	68.37%

Regulars· Nov 4

Henry Schein's Q3 earnings and revenue beat expectations, with adjusted EPS at $1.38 and revenue at $3.34B.
The company's partnership with KKR has been expanded to allow KKR to increase its ownership to 19.9% through market purchases.
Henry Schein's Q3 results saw a 5.2% YoY increase in revenue, with strong growth in dental and medical distribution, and a net income of $101m.

Newcomers· Feb 24

Newcomers to discussing $HSIC are focused on the company's debt-to-equity ratio shift, which usually signals caution, despite the stock hitting a 52-week high.
The recent Q4 earnings beat has sparked a potential momentum shift, with profit rising to $101M ($0.85/share) vs. $94M ($0.74/share) last year, and underlying strength suggested by the bottom-line growth.
$HSIC's Q4 earnings beat expectations, with revenue exceeding estimates by 98.9M and EPS exceeding estimates by 0.04, but the EPS miss has led to a mixed reaction, with revenue beating and EPS missing.

Generated by AI

Henry Schein has delivered a 30.7% share price gain over the past year, which naturally puts the spotlight on whether that move is backed by the cash the business is expected to generate. With the stock recently closing at US$86.37, the key issue now is how that price lines up against the value suggested by its cash flows. The 30.7% return over the past 12 months raises a straightforward question for holders and potential buyers: whether the cash that Henry Schein can produce is enough to...

4d agoYahoo Finance

Transcript: Henry Schein Q2 2026 Earnings Conference Call - Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ:HSIC) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and

5d agoBenzinga

Is Henry Schein Stock Outperforming the Dow?

Henry Schein has outperformed the Dow over the past year, and analysts are cautiously optimistic about the stock’s prospects.

5d agoYahoo Finance

Henry Schein Inc. stock underperforms Wednesday when compared to competitors

6d agoMarketWatch

Henry Schein Expands and Extends Revolving Credit Facility

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Also Discussed

Investors talking about HSIC also mention

#	Name	Attention
1	PDCO - Patterson Companies, Inc.	——
2	Dentsply Sirona Inc.XRAY	0%new
3	Encompass Health CorporationEHC	0%0
4	Align Technology Inc.ALGN	0%new
5	Penumbra Inc.PEN	0%new
6	Expeditors International of Washington Inc.EXPD	0%0
7	HOLX - Hologic, Inc.	——
8	IDEXX Laboratories, Inc.IDXX	0%0
9	Bright Horizons Family Solutions IncBFAM	0%new
10	W.W. Grainger, Inc.GWW	0%0

Henry Schein, Inc.

Healthcare
Medical Distribution

Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals. Henry Schein provides a broad range of products and services through its core businesses in healthcare distribution, specialty products, and technology-enabled value-added services. Its offerings include consumable supplies, dental equipment, practice-management software, logistics support, and related clinical solutions that help practices manage daily operations more efficiently. The company also supports dental laboratories, government and institutional health care clinics, and other alternate care sites with products and services tailored to professional workflows. With a strong presence in dental and medical markets, Henry Schein plays an important role in the supply chain for outpatient health care providers and practice support services.

Website

Location

135 Duryea Road

Melville, NY, 11747

United States

Social

What share of all stock conversation is about HSIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 4

$HSIC reported Q2 FY26 results with strong sales and earnings growth, beating estimates on both revenue and EPS.
Management raised full-year guidance across the board, including a subtle but meaningful upgrade to EBITDA growth expectations.
Henry Schein's Q2 FY26 GAAP diluted EPS was $0.82, and total net sales were $3.5 billion, an increase of 6.7% compared to the same period last year.

Generated by AI

Sentiment

Of the messages about HSIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.74% -13.94
Bearish	—	—	—	40.26% +13.94

Bullish· Feb 24

$HSIC's Q4 2025 earnings beat expectations, with a 7.7% YoY revenue growth and a 4.0% full-year revenue growth.
The company's positive 2026 outlook and $850M share buyback plan indicate a strong financial position and potential for future growth.
$HSIC's stock price surged 4.8% post-earnings, with a revenue beat and underlying strength in the bottom-line growth suggesting a potential momentum shift.

Bearish· Dec 6

Henry Schein has been downgraded to underweight by Morgan Stanley, indicating a bearish outlook on the company's stock.
The stock's price may continue to drop, potentially reaching as low as $60 or $52, due to a broader market correction and similar historical patterns.
Shorting Henry Schein and another company, PDCO, may be a viable strategy following news that they have become targets of a larger company, dubbed the "Death Star".

Generated by AI

Topics

Of the messages about HSIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	59.6%
Analysts	—	—	0%	10.4%
Earnings	—	—	0%	13.2%
Controversies	—	—	0%	0%
Macro	—	—	0%	4%
Technical Analysis	—	—	0%	12.8%

Earnings· Nov 13

Henry Schein's Q3 earnings met expectations at $1.32 per share, but revenue missed the consensus at $3.16 billion, a 3.1% year-over-year increase.
The company lowered its full-year 2023 guidance for adjusted EPS to $4.43-$4.71, citing softening macroeconomic conditions and a business interruption impact from a cybersecurity incident.
Henry Schein's Q3 revenue growth was driven by stable net sales, with total net sales reaching $3.2 billion, an increase of 3.1% compared to the third quarter of 2022.

Analysts· Feb 16

Morgan Stanley analyst Erin Wright maintains Henry Schein ($HSIC) with an Underweight rating and raises the price target from $67 to $72.
Credit Suisse analyst Matt Miksic maintains Henry Schein ($HSIC) with an Outperform rating and raises the price target from $90 to $100.
Robert W. Baird and Barrington Research have raised their price targets for Henry Schein ($HSIC) to $103.00 and $102.00, respectively.

Announcements· Nov 13

Henry Schein, Inc. ($HSIC) reported Q3 2023 financial results, with adjusted EPS of $1.32 and revenue of $3.2B, missing consensus estimates.
The company updated its full-year guidance, lowering adjusted EPS to $4.43-$4.71 and revenue outlook to -3% to -1% due to a softening macro picture and a cybersecurity incident.
Henry Schein's shares fell 3.07% in pre-market trading after the report, citing lower sales of PPE products and COVID-19 test kits, but the company's technology, value-added services, and dental specialty products contributed to profitability.

Generated by AI

Community

Of the messages about HSIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	31.63%
Newcomers	—	—	100%	68.37%

Regulars· Nov 4

Henry Schein's Q3 earnings and revenue beat expectations, with adjusted EPS at $1.38 and revenue at $3.34B.
The company's partnership with KKR has been expanded to allow KKR to increase its ownership to 19.9% through market purchases.
Henry Schein's Q3 results saw a 5.2% YoY increase in revenue, with strong growth in dental and medical distribution, and a net income of $101m.

Newcomers· Feb 24

Newcomers to discussing $HSIC are focused on the company's debt-to-equity ratio shift, which usually signals caution, despite the stock hitting a 52-week high.
The recent Q4 earnings beat has sparked a potential momentum shift, with profit rising to $101M ($0.85/share) vs. $94M ($0.74/share) last year, and underlying strength suggested by the bottom-line growth.
$HSIC's Q4 earnings beat expectations, with revenue exceeding estimates by 98.9M and EPS exceeding estimates by 0.04, but the EPS miss has led to a mixed reaction, with revenue beating and EPS missing.

Generated by AI

Henry Schein

Social

Aug 4

Bullish· Feb 24

Bearish· Dec 6

Earnings· Nov 13

Analysts· Feb 16

Announcements· Nov 13

Regulars· Nov 4

Newcomers· Feb 24

Henry Schein (HSIC): Buy, Sell, or Hold Post Q2 Earnings?

Henry Schein (HSIC) Stock Looks Below Fair Value Even After A 31% Gain

Transcript: Henry Schein Q2 2026 Earnings Conference Call - Henry Schein (NASDAQ:HSIC)

Is Henry Schein Stock Outperforming the Dow?

Henry Schein Inc. stock underperforms Wednesday when compared to competitors

Henry Schein Expands and Extends Revolving Credit Facility

Also Discussed

Henry Schein, Inc.

Company Information

Location

Henry Schein (HSIC): Buy, Sell, or Hold Post Q2 Earnings?

Henry Schein (HSIC) Stock Looks Below Fair Value Even After A 31% Gain

Transcript: Henry Schein Q2 2026 Earnings Conference Call - Henry Schein (NASDAQ:HSIC)

Is Henry Schein Stock Outperforming the Dow?

Henry Schein Inc. stock underperforms Wednesday when compared to competitors

Henry Schein Expands and Extends Revolving Credit Facility

Also Discussed

Social

Aug 4

Bullish· Feb 24

Bearish· Dec 6

Earnings· Nov 13

Analysts· Feb 16

Announcements· Nov 13

Regulars· Nov 4

Newcomers· Feb 24